Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin''s lymphoma. (January 2012)

• Record Type: Journal Article
• Authors: Beaven, Anne W; Rizzieri, David
• Is Part Of: Clinical investigation. Volume 2:Number 1(2012)
• Page Start: 49
• Page End: 58
• Publication Date: 2012-01
• Subjects: anthracycline -- aza-anthracenedione -- BBR-2778 -- diffuse large B-cell lymphoma -- pixantrone; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical trials -- Periodicals; 615.580724
• DOI: 10.4155/cli.11.170
• Languages: English
• ISSNs: 2041-6806

Abstract

Diffuse large B-cell lymphoma is the most common non-Hodgkin''s lymphoma. Although over 50% of patients are cured with first-line therapy that includes an anthracycline, there are a number of patients who require systemic therapy for relapsed or refractory disease. Currently, no drug is approved for this indication. Pixantrone, a novel aza-anthracenedione, was developed to maintain clinical efficacy while minimizing the cardiac toxicity associated with anthracyclines. Initial results of clinical trials demonstrate that pixantrone induces responses in this difficult-to-treat patient population with tolerable side effects. Results of ongoing clinical trials will better define pixantrone''s role in treating diffuse large B-cell lymphoma and help assess its long-term cardiac toxicity.